Enhancing the Therapeutic Profile of Dapagliflozin: Chitosan Nanoparticle Encapsulation for Intestinal Applications
FASEB BioAdvances · 2026-05 · 8 (5)
DOI: 10.1096/fba.2026-00050 ↗Kurz gefasst
Fachartikel in der Zeitschrift FASEB BioAdvances, online erschienen am 14.05.2026. Verfasst von Agni Klonari und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medicine, School of Health Sciences University of Ioannina Ioannina Greece. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Dapagliflozin is a sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitor primarily used to treat type 2 diabetes by lowering blood glucose levels. In addition to its antidiabetic action, it has demonstrated cardioprotective and renoprotective effects, along with antioxidant, anti‐inflammatory, and anticancer activities. Encapsulation of dapagliflozin in nanocarriers represents an innovative strategy to improve existing therapies and develop targeted treatments. Such formulations can enhance solubility and stability, improve epithelial permeability and bioavailability, and reduce potential side effects. This study investigates the cellular and molecular effects of dapagliflozin encapsulated in chitosan nanoparticles, focusing on colon (Caco‐2) cells. The findings showed that free dapagliflozin significantly reduced cell viability, whereas the encapsulated form preserved high cell viability. In addition, the encapsulated drug effectively reduced reactive oxygen species levels, maintaining its antioxidant activity. Free dapagliflozin did not increase the expression of Nrf2, NFκB, or HO‐1 signaling pathways. In contrast, encapsulation in chitosan nanoparticles resulted in increased expression of all three pathways, indicating potential regulatory involvement in these signaling mechanisms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiology, Faculty of Medicine, School of Health Sciences University of Ioannina Ioannina Greece.
- Nanomedicine and Nanobiotechnology Research Group University of Ioannina Ioannina Greece.
- Laboratory of Biotechnology, Department of Biological Applications and Technologies University of Ioannina Ioannina Greece.
- Microbiology Department, School of Health Science, Faculty of Medicine University of Ioannina Ioannina Greece.
ORCID-Profile: Yannis V Simos
Zitieren
APA
Klonari, A., Athinodorou, A. M., Papanikolaou, E., Skonta, A., Bellou, M. G., Lakkas, L., Tsamis, K. I., Markopoulos, G. S., Stamatis, H., Bozidis, P., Peschos, D., & Simos, Y. V. (2026). Enhancing the Therapeutic Profile of Dapagliflozin: Chitosan Nanoparticle Encapsulation for Intestinal Applications. FASEB BioAdvances, 8(5). https://doi.org/10.1096/fba.2026-00050
Vancouver
Klonari A, Athinodorou AM, Papanikolaou E, Skonta A, Bellou MG, Lakkas L, et al. Enhancing the Therapeutic Profile of Dapagliflozin: Chitosan Nanoparticle Encapsulation for Intestinal Applications. FASEB BioAdvances. 2026;8(5). doi:10.1096/fba.2026-00050
BibTeX
@article{Klonari2026,
author = {Klonari, Agni and Athinodorou, Antrea-Maria and Papanikolaou, Eirini and Skonta, Anastasia and Bellou, Myrto G and Lakkas, Lampros and Tsamis, Konstantinos I and Markopoulos, Georgios S and Stamatis, Haralambos and Bozidis, Petros and Peschos, Dimitrios and Simos, Yannis V},
title = {Enhancing the Therapeutic Profile of Dapagliflozin: Chitosan Nanoparticle Encapsulation for Intestinal Applications},
journal = {FASEB BioAdvances},
year = {2026},
volume = {8},
number = {5},
doi = {10.1096/fba.2026-00050}
}
EUVIMED